Job for MSc, B.Pharm as Team Member at Cipla


Cipla has applied for permission from DCGI to market Favipiravir in India as an experimental medicine for COVID-19. Under the guidances of ICMR, Cipla will also conduct a suitable limited trial prior to marketing the product as Ciplenza.